KCT0007792已完成未知
A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of FSH-SP-S for skin health
FromBIO0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 30(Year) 至 60(Year)（—）
- 性别
- Female
入选标准
- •1) Women aged 30 to 60
- •2) A person with dry skin (skin moisture index of 49 or less) and who has begun to produce wrinkles around the eyes according to the visual evaluation
- •3) A person who voluntarily agrees to participate in the human body application test and signs informed consent form.
排除标准
- •1) A person with sensitive, hypersensitive, and eczema skin diseases (atopic dermatitis, suppurative acne, eczema, etc.)
- •2) A person who has skin abnormalities such as acne, erythema, spots, capillary dilatation, burn marks, scars, tattoos, etc. at the test site (measuring part)
- •3) A person who has continuously applied or consumed placental-containing cosmetics, medicines, and non-drugs for at least one month, within three months prior to participating in the study
- •4) A person who is taking health functional food, non-drugs, or other processed food for the purpose of moisturizing the skin and improving wrinkles
- •5) A person who has undergone dermatological procedures including skin dermis and Botox within 6 months before participating in the study
- •6) Pregnant women, lactating women and those with plans for pregnancy within the next six months
- •7) A person on oral contraceptives
- •8) A person who is allergic to cosmetics, medicines, non-drugs, or ultraviolet rays or sunlight
- •9) A person who is constantly exposed to excessive sunlight or ultraviolet rays or plan to do so (e.g., outdoor sports (swimming, skiing, hiking), driving, walking travel, tanning, etc.)
- •10) A person with hypertension and diabetes who are not controlled even though they are on medication
- •11) A person with renal dysfunction (increased more than 1.5 times the normal upper limit of creatine) and liver dysfunction (increased more than 2.5 times the normal upper limit of AST, ALT)
- •12) A person with chronic gastrointestinal disorders, autoimmune diseases, malignancy, mental illness and alcoholism
- •13) A person who is allergic to or overreacted to the ingredients of the test product
- •14) A person who has participated in another clinical trial or human application test one month before the start of the test
- •15) A person deemed inappropriate by the principal investigator to participate in the research
研究者
相似试验
进行中（未招募）
1 期
A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution byinhalation.Autoimmune Pulmonary Alveolar Proteinosis (aPAP)MedDRA version: 21.1Level: LLTClassification code 10037316Term: Pulmonary alveolar proteinosisSystem Organ Class: 100000004855EUCTR2020-001263-85-ROSavara ApS160
已完成
不适用
Clinical trial of fluoride varnish in preventing dental caries of Sjögren’s syndrome patientsISRCTN85164658Research Grants Council of Hong Kong120
尚未招募
3 期
Clinical study for validating the effectiveness of Tendoease tablet in the rehabilitation of tendonitis.CTRI/2024/03/064125Meyer Organics Pvt Ltd
已完成
3 期
Herbal formulation clinical trial for immune supportCTRI/2020/02/023359Botanic Healthcare Pvt Ltd
招募中
3 期
Once-daily inhaled molgramostim nebulizer solution in aPAP.Autoimmune Pulmonary Alveolar Proteinosis(aPAP)JPRN-jRCT2051210036Desai Dhaval40